{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:53:44Z","timestamp":1790409224449,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","trasci.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.transci.2018.10.011","type":"journal-article","created":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T16:48:34Z","timestamp":1540918114000},"page":"717-720","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Management of acquired hemophilia A: Review of current evidence"],"prefix":"10.1016","volume":"57","author":[{"given":"Janie","family":"Charlebois","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges-\u00c9tienne","family":"Rivard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"St-Louis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"January (Suppl. 1)","key":"10.1016\/j.transci.2018.10.011_bib0005","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2298\/SARH10S1064E","article-title":"Acquired haemophilia syndrome: pathophysiology and therapy","volume":"138","author":"Elezovic","year":"2010","journal-title":"Srp Arh Celok Lek"},{"key":"10.1016\/j.transci.2018.10.011_bib0010","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1182\/asheducation.V2012.1.369.3798356","article-title":"Therapeutic challenges in acquired factor VIII deficiency","volume":"2012","author":"Collins","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"October (9)","key":"10.1016\/j.transci.2018.10.011_bib0015","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1080\/10245332.2017.1319115","article-title":"Acquired hemophilia A: a review of recent data and new therapeutic options","volume":"22","author":"Franchini","year":"2017","journal-title":"Hematology"},{"issue":"August (4)","key":"10.1016\/j.transci.2018.10.011_bib0020","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11739-010-0380-y","article-title":"Diagnosis, laboratory aspects and management of acquired hemophilia A","volume":"5","author":"Toschi","year":"2010","journal-title":"Intern Emerg Med"},{"issue":"Junuary 3","key":"10.1016\/j.transci.2018.10.011_bib0025","article-title":"Consensus recommendations for the diagnosis and treatment of acquired hemophilia A","volume":"7","author":"Collins","year":"2010","journal-title":"BMC Res Notes"},{"issue":"April (4)","key":"10.1016\/j.transci.2018.10.011_bib0030","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3324\/haematol.2008.001743","article-title":"International recommendations on the diagnosis and treatment of patients with acquired hemophilia A","volume":"94","author":"Huth-Kuhne","year":"2009","journal-title":"Haematologica"},{"issue":"March (3)","key":"10.1016\/j.transci.2018.10.011_bib0035","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.bcmd.2014.11.012","article-title":"Challenges and open issues in the management of acquired hemophilia A (AHA)","volume":"54","author":"Shetty","year":"2015","journal-title":"Blood Cells Mol Dis"},{"issue":"October (4)","key":"10.1016\/j.transci.2018.10.011_bib0040","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/pbc.22657","article-title":"Acquired hemophilia in pediatrics: a systematic review","volume":"55","author":"Franchini","year":"2010","journal-title":"Pediatr Blood Cancer"},{"issue":"July (3)","key":"10.1016\/j.transci.2018.10.011_bib0045","first-page":"498","article-title":"Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management","volume":"13","author":"Franchini","year":"2015","journal-title":"Blood Transfus"},{"issue":"November (48)","key":"10.1016\/j.transci.2018.10.011_bib0050","article-title":"Influence of factor VIII level and its inhibitor titer on the therapeutic response to corticosteroids alone in the management of acquired hemophilia: a retrospective single-center study","volume":"95","author":"Vautier","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"September (6)","key":"10.1016\/j.transci.2018.10.011_bib0055","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/bjh.12463","article-title":"Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO","volume":"162","author":"W Collins","year":"2013","journal-title":"Br J Haematol"},{"issue":"July (Suppl 1","key":"10.1016\/j.transci.2018.10.011_bib0060","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1538-7836.2011.04309.x","article-title":"Management of acquired haemophilia A","volume":"9","author":"Collins","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"December (6)","key":"10.1016\/j.transci.2018.10.011_bib0065","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1160\/TH13-05-0363","article-title":"Acquired haemophilia A: a 2013 update","volume":"110","author":"Franchini","year":"2013","journal-title":"Thromb Haemost"},{"issue":"July (7)","key":"10.1016\/j.transci.2018.10.011_bib0070","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/ajh.24777","article-title":"Acquired hemophilia A: updated review of evidence and treatment guidance","volume":"92","author":"Kruse-Jarres","year":"2017","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.transci.2018.10.011_bib0075","first-page":"311","volume":"35","author":"Tiede","year":"2015","journal-title":"Management of acquired haemophilia A. Hamostaseologie"},{"issue":"December (4)","key":"10.1016\/j.transci.2018.10.011_bib0080","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1046\/j.1468-0734.2001.00049.x","article-title":"Acquired hemophilia","volume":"5","author":"Boggio","year":"2001","journal-title":"Rev Clin Exp Hematol"},{"issue":"January (1)","key":"10.1016\/j.transci.2018.10.011_bib0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.revmed.2012.08.005","article-title":"H\u00e9mophilie acquise : des donn\u00e9es des registres aux recommandations th\u00e9rapeutiques","volume":"34","author":"L\u00e9vesque","year":"2013","journal-title":"La Revue de M\u00e9decine Interne"},{"issue":"July (5)","key":"10.1016\/j.transci.2018.10.011_bib0090","first-page":"433","article-title":"Acquired inhibitors of coagulation factors: part I-acquired hemophilia A","volume":"38","author":"Coppola","year":"2012","journal-title":"Semin Thromb Hemost"},{"issue":"December (Suppl 81","key":"10.1016\/j.transci.2018.10.011_bib0095","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/ejh.12689","article-title":"Acquired haemophilia: an overview for clinical practice","volume":"95","author":"Kessler","year":"2015","journal-title":"Eur J Haematol"},{"issue":"May 6","key":"10.1016\/j.transci.2018.10.011_bib0100","first-page":"143","article-title":"Acquired hemophilia A: emerging treatment options","volume":"8","author":"Janbain","year":"2015","journal-title":"J Blood Med"},{"issue":"May (102)","key":"10.1016\/j.transci.2018.10.011_bib0105","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1365-2516.2010.02232.x","article-title":"Diagnosis and treatment of acquired haemophilia","volume":"16","author":"Baudo","year":"2010","journal-title":"Haemophilia"},{"issue":"July (1)","key":"10.1016\/j.transci.2018.10.011_bib0110","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2012-02-408930","article-title":"Management of bleeding in acquired hemophilia A: results from the European acquired Haemophilia (EACH2) Registry","volume":"120","author":"Baudo","year":"2012","journal-title":"Blood"},{"issue":"December (1)","key":"10.1016\/j.transci.2018.10.011_bib0115","article-title":"Perioperative management of acquired hemophilia a: a case report and review of literature","volume":"4","author":"Ilkhchoui","year":"2013","journal-title":"Anesth Pain Med"},{"issue":"January (1)","key":"10.1016\/j.transci.2018.10.011_bib0120","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1111\/hae.12852","article-title":"US experience with recombinant factor VIIa for surgery and other invasive procedures in acquired haemophilia: analysis from the Hemostasis and Thrombosis Research Society Registry","volume":"22","author":"Ma","year":"2016","journal-title":"Haemophilia"},{"issue":"May (3)","key":"10.1016\/j.transci.2018.10.011_bib0125","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/hae.12574","article-title":"FEIBA in the treatment of acquired haemophilia A: results from the prospective multicentre French\u2019 FEIBA dans l\u2019hemophilie A acquise\u2019 (FEIBHAC) registry","volume":"21","author":"Borg","year":"2015","journal-title":"Haemophilia"},{"issue":"December (6)","key":"10.1016\/j.transci.2018.10.011_bib0130","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.thromres.2015.10.032","article-title":"Activated prothrombin complex concentrate (FEIBA\u00ae) for the treatment and prevention of bleeding in patients with acquired haemophilia: a sequential study","volume":"136","author":"Zanon","year":"2015","journal-title":"Thromb Res"},{"issue":"October (7)","key":"10.1016\/j.transci.2018.10.011_bib0135","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/MBC.0000000000000471","article-title":"Use of recombinant activated factor VII for acute bleeding episodes in acquired hemophilia: final analysis from the Hemostasis and Thrombosis Research Society Registry acquired hemophilia study","volume":"27","author":"Ma","year":"2016","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"June (Supplement 1)","key":"10.1016\/j.transci.2018.10.011_bib0140","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S0268-960X(15)30004-7","article-title":"The use of recombinant activated factor VII in patients with acquired haemophilia","volume":"29","author":"Tiede","year":"2015","journal-title":"Blood Rev"},{"issue":"May (7)","key":"10.1016\/j.transci.2018.10.011_bib0145","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s40265-016-0576-1","article-title":"Susoctocog alfa: a review in acquired haemophilia a","volume":"76","author":"Burness","year":"2016","journal-title":"Drugs"},{"issue":"August (4)","key":"10.1016\/j.transci.2018.10.011_bib0150","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1586\/17474086.2015.1040758","article-title":"Recombinant B domain deleted porcine factor VIII for the treatment of bleeding episodes in adults with acquired hemophilia A","volume":"8","author":"Gomperts","year":"2015","journal-title":"Expert Rev Hematol"},{"issue":"July (4)","key":"10.1016\/j.transci.2018.10.011_bib0155","first-page":"365","article-title":"Porcine recombinant factor VIII: an additional weapon to handle anti-factor VIII antibodies","volume":"15","author":"Mannucci","year":"2017","journal-title":"Blood Transfus"},{"issue":"July (1)","key":"10.1016\/j.transci.2018.10.011_bib0160","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2012-02-409185","article-title":"Immunosuppression for acquired hemophilia A: results from the European acquired Haemophilia Registry (EACH2)","volume":"120","author":"Collins","year":"2012","journal-title":"Blood"},{"issue":"September (3)","key":"10.1016\/j.transci.2018.10.011_bib0165","first-page":"187","article-title":"Systemic therapy in acquired haemophilia - a single institute experience","volume":"85","author":"Sarah","year":"2016","journal-title":"Ulster Med J"},{"issue":"May (19)","key":"10.1016\/j.transci.2018.10.011_bib0170","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1182\/blood-2015-09-672774","article-title":"Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01\/2010 study","volume":"127","author":"Tiede","year":"2016","journal-title":"Blood"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050218304300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050218304300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T22:20:21Z","timestamp":1720736421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050218304300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S1473050218304300"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2018.10.011","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of acquired hemophilia A: Review of current evidence","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2018.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}